Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.

Abstract

The NPM-ALK fusion protein is found in ALK(+) anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK(+) anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK(+) anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.

• Authors: James M Cleary, Scott Rodig, Paul M Barr, Atul B Shinagare, Jeffrey W Clark, Geoffrey I Shapiro, Philippe Armand
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 12 Issue 3 Pg. 323-6; quiz 326 (Mar 01 2014) ISSN: 1540-1413 [Electronic] United States
• PMID: 24616538 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Pyrazoles
• Pyridines
• Crizotinib

Topics

• Adult
• Antineoplastic Agents (therapeutic use)
• Crizotinib
• Hematopoietic Stem Cell Transplantation
• Humans
• Lymphoma, Large-Cell, Anaplastic (diagnosis, therapy)
• Maintenance Chemotherapy
• Male
• Positron-Emission Tomography
• Protein Kinase Inhibitors (therapeutic use)
• Pyrazoles (therapeutic use)
• Pyridines (therapeutic use)
• Salvage Therapy
• Tomography, X-Ray Computed
• Transplantation, Homologous
• Treatment Outcome